MCL coexpression mm9:160: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
|coexpression_dpi_cluster_scores_median=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.167422152083431,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.0421182837367051,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.320628757845611,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.122755080632381,0.0711694759496908,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.575801202808435,0.590467880124659,0.671827077421888,0.710380939222763,0.847572229428273,0.66077252340634,0.479642349719964,0.225507821441585,0.0246533883946583,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0 | |coexpression_dpi_cluster_scores_median=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.167422152083431,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.0421182837367051,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.320628757845611,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.122755080632381,0.0711694759496908,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.575801202808435,0.590467880124659,0.671827077421888,0.710380939222763,0.847572229428273,0.66077252340634,0.479642349719964,0.225507821441585,0.0246533883946583,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0 | ||
|gostat_on_MCL_coexpression=GO:0045137;development of primary sexual characteristics;0.00564388892742367;11705,13363,18595!GO:0006694;steroid biosynthetic process;0.00564388892742367;13074,15487,15485!GO:0007548;sex differentiation;0.00564388892742367;11705,13363,18595!GO:0003006;reproductive developmental process;0.0069094056575987;11705,13363,18595!GO:0016229;steroid dehydrogenase activity;0.0134672247436423;15487,15485!GO:0046546;development of primary male sexual characteristics;0.0135048765320258;13363,18595!GO:0046661;male sex differentiation;0.0146140807144875;13363,18595!GO:0008202;steroid metabolic process;0.0146140807144875;13074,15487,15485!GO:0042446;hormone biosynthetic process;0.0222495706780046;13074,15485!GO:0007506;gonadal mesoderm development;0.0257206979977026;11705!GO:0046655;folic acid metabolic process;0.0257206979977026;14275!GO:0004508;steroid 17-alpha-monooxygenase activity;0.0257206979977026;13074!GO:0047045;testosterone 17-beta-dehydrogenase (NADP+) activity;0.0257206979977026;15487!GO:0022414;reproductive process;0.0257206979977026;11705,13363,18595!GO:0008406;gonad development;0.0267817631548365;11705,13363!GO:0048608;reproductive structure development;0.0271045687618472;11705,13363!GO:0008610;lipid biosynthetic process;0.0289954205108826;13074,15487,15485!GO:0004714;transmembrane receptor protein tyrosine kinase activity;0.0289954205108826;18595,18211!GO:0005515;protein binding;0.0289954205108826;13363,13043,20295,13684,14229,77057,11705,65116,13617,18595,18211!GO:0008429;phosphatidylethanolamine binding;0.0289954205108826;11744!GO:0006703;estrogen biosynthetic process;0.0289954205108826;15485!GO:0004962;endothelin receptor activity;0.0289954205108826;13617!GO:0048407;platelet-derived growth factor binding;0.0289954205108826;18595!GO:0033327;Leydig cell differentiation;0.0289954205108826;13363!GO:0019199;transmembrane receptor protein kinase activity;0.0306867376359688;18595,18211!GO:0042445;hormone metabolic process;0.0306867376359688;13074,15485!GO:0030809;negative regulation of nucleotide biosynthetic process;0.0306867376359688;13617!GO:0006620;posttranslational protein targeting to membrane;0.0306867376359688;14275!GO:0030908;protein splicing;0.0306867376359688;13363!GO:0030818;negative regulation of cAMP biosynthetic process;0.0306867376359688;13617!GO:0016539;intein-mediated protein splicing;0.0306867376359688;13363!GO:0030815;negative regulation of cAMP metabolic process;0.0306867376359688;13617!GO:0030803;negative regulation of cyclic nucleotide biosynthetic process;0.0306867376359688;13617!GO:0030800;negative regulation of cyclic nucleotide metabolic process;0.0306867376359688;13617!GO:0008210;estrogen metabolic process;0.0375225372766592;15485!GO:0045980;negative regulation of nucleotide metabolic process;0.0375225372766592;13617!GO:0008517;folic acid transporter activity;0.0375225372766592;14275!GO:0009058;biosynthetic process;0.0375225372766592;13684,13074,15487,15485,13617!GO:0030817;regulation of cAMP biosynthetic process;0.0434324089209833;13617!GO:0006704;glucocorticoid biosynthetic process;0.0434324089209833;13074!GO:0016616;oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor;0.0445127194766519;15487,15485!GO:0030539;male genitalia development;0.047248571028189;18595!GO:0005160;transforming growth factor beta receptor binding;0.047248571028189;11705!GO:0030814;regulation of cAMP metabolic process;0.047248571028189;13617!GO:0016614;oxidoreductase activity, acting on CH-OH group of donors;0.047248571028189;15487,15485! | |gostat_on_MCL_coexpression=GO:0045137;development of primary sexual characteristics;0.00564388892742367;11705,13363,18595!GO:0006694;steroid biosynthetic process;0.00564388892742367;13074,15487,15485!GO:0007548;sex differentiation;0.00564388892742367;11705,13363,18595!GO:0003006;reproductive developmental process;0.0069094056575987;11705,13363,18595!GO:0016229;steroid dehydrogenase activity;0.0134672247436423;15487,15485!GO:0046546;development of primary male sexual characteristics;0.0135048765320258;13363,18595!GO:0046661;male sex differentiation;0.0146140807144875;13363,18595!GO:0008202;steroid metabolic process;0.0146140807144875;13074,15487,15485!GO:0042446;hormone biosynthetic process;0.0222495706780046;13074,15485!GO:0007506;gonadal mesoderm development;0.0257206979977026;11705!GO:0046655;folic acid metabolic process;0.0257206979977026;14275!GO:0004508;steroid 17-alpha-monooxygenase activity;0.0257206979977026;13074!GO:0047045;testosterone 17-beta-dehydrogenase (NADP+) activity;0.0257206979977026;15487!GO:0022414;reproductive process;0.0257206979977026;11705,13363,18595!GO:0008406;gonad development;0.0267817631548365;11705,13363!GO:0048608;reproductive structure development;0.0271045687618472;11705,13363!GO:0008610;lipid biosynthetic process;0.0289954205108826;13074,15487,15485!GO:0004714;transmembrane receptor protein tyrosine kinase activity;0.0289954205108826;18595,18211!GO:0005515;protein binding;0.0289954205108826;13363,13043,20295,13684,14229,77057,11705,65116,13617,18595,18211!GO:0008429;phosphatidylethanolamine binding;0.0289954205108826;11744!GO:0006703;estrogen biosynthetic process;0.0289954205108826;15485!GO:0004962;endothelin receptor activity;0.0289954205108826;13617!GO:0048407;platelet-derived growth factor binding;0.0289954205108826;18595!GO:0033327;Leydig cell differentiation;0.0289954205108826;13363!GO:0019199;transmembrane receptor protein kinase activity;0.0306867376359688;18595,18211!GO:0042445;hormone metabolic process;0.0306867376359688;13074,15485!GO:0030809;negative regulation of nucleotide biosynthetic process;0.0306867376359688;13617!GO:0006620;posttranslational protein targeting to membrane;0.0306867376359688;14275!GO:0030908;protein splicing;0.0306867376359688;13363!GO:0030818;negative regulation of cAMP biosynthetic process;0.0306867376359688;13617!GO:0016539;intein-mediated protein splicing;0.0306867376359688;13363!GO:0030815;negative regulation of cAMP metabolic process;0.0306867376359688;13617!GO:0030803;negative regulation of cyclic nucleotide biosynthetic process;0.0306867376359688;13617!GO:0030800;negative regulation of cyclic nucleotide metabolic process;0.0306867376359688;13617!GO:0008210;estrogen metabolic process;0.0375225372766592;15485!GO:0045980;negative regulation of nucleotide metabolic process;0.0375225372766592;13617!GO:0008517;folic acid transporter activity;0.0375225372766592;14275!GO:0009058;biosynthetic process;0.0375225372766592;13684,13074,15487,15485,13617!GO:0030817;regulation of cAMP biosynthetic process;0.0434324089209833;13617!GO:0006704;glucocorticoid biosynthetic process;0.0434324089209833;13074!GO:0016616;oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor;0.0445127194766519;15487,15485!GO:0030539;male genitalia development;0.047248571028189;18595!GO:0005160;transforming growth factor beta receptor binding;0.047248571028189;11705!GO:0030814;regulation of cAMP metabolic process;0.047248571028189;13617!GO:0016614;oxidoreductase activity, acting on CH-OH group of donors;0.047248571028189;15487,15485! | ||
|ontology_enrichment_celltype= | |||
|ontology_enrichment_disease= | |||
|ontology_enrichment_uberon=UBERON:0000991!6.98e-58!18;UBERON:0005564!6.98e-58!18;UBERON:0004176!3.36e-52!17;UBERON:0009196!3.36e-52!17;UBERON:0009117!3.36e-52!17;UBERON:0000473!1.93e-44!14;UBERON:0003133!3.79e-43!24;UBERON:0003135!2.02e-41!15;UBERON:0005156!9.62e-40!26;UBERON:0000990!9.62e-40!26;UBERON:0003101!8.85e-39!16;UBERON:0000079!8.85e-39!16;UBERON:0002323!1.39e-27!37;UBERON:0004458!1.39e-27!37;UBERON:0003886!7.96e-27!38;UBERON:0002553!4.17e-26!39;UBERON:0000464!1.84e-17!57;UBERON:0000466!3.23e-12!79;UBERON:0000992!4.66e-09!3;UBERON:0000926!6.15e-09!120;UBERON:0004120!6.15e-09!120;UBERON:0006603!6.15e-09!120 | |||
}} | }} |
Revision as of 17:08, 11 October 2012
Phase1 CAGE Peaks
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0045137 | development of primary sexual characteristics | 0.00564388892742367 |
GO:0006694 | steroid biosynthetic process | 0.00564388892742367 |
GO:0007548 | sex differentiation | 0.00564388892742367 |
GO:0003006 | reproductive developmental process | 0.0069094056575987 |
GO:0016229 | steroid dehydrogenase activity | 0.0134672247436423 |
GO:0046546 | development of primary male sexual characteristics | 0.0135048765320258 |
GO:0046661 | male sex differentiation | 0.0146140807144875 |
GO:0008202 | steroid metabolic process | 0.0146140807144875 |
GO:0042446 | hormone biosynthetic process | 0.0222495706780046 |
GO:0007506 | gonadal mesoderm development | 0.0257206979977026 |
GO:0046655 | folic acid metabolic process | 0.0257206979977026 |
GO:0004508 | steroid 17-alpha-monooxygenase activity | 0.0257206979977026 |
GO:0047045 | testosterone 17-beta-dehydrogenase (NADP+) activity | 0.0257206979977026 |
GO:0022414 | reproductive process | 0.0257206979977026 |
GO:0008406 | gonad development | 0.0267817631548365 |
GO:0048608 | reproductive structure development | 0.0271045687618472 |
GO:0008610 | lipid biosynthetic process | 0.0289954205108826 |
GO:0004714 | transmembrane receptor protein tyrosine kinase activity | 0.0289954205108826 |
GO:0005515 | protein binding | 0.0289954205108826 |
GO:0008429 | phosphatidylethanolamine binding | 0.0289954205108826 |
GO:0006703 | estrogen biosynthetic process | 0.0289954205108826 |
GO:0004962 | endothelin receptor activity | 0.0289954205108826 |
GO:0048407 | platelet-derived growth factor binding | 0.0289954205108826 |
GO:0033327 | Leydig cell differentiation | 0.0289954205108826 |
GO:0019199 | transmembrane receptor protein kinase activity | 0.0306867376359688 |
GO:0042445 | hormone metabolic process | 0.0306867376359688 |
GO:0030809 | negative regulation of nucleotide biosynthetic process | 0.0306867376359688 |
GO:0006620 | posttranslational protein targeting to membrane | 0.0306867376359688 |
GO:0030908 | protein splicing | 0.0306867376359688 |
GO:0030818 | negative regulation of cAMP biosynthetic process | 0.0306867376359688 |
GO:0016539 | intein-mediated protein splicing | 0.0306867376359688 |
GO:0030815 | negative regulation of cAMP metabolic process | 0.0306867376359688 |
GO:0030803 | negative regulation of cyclic nucleotide biosynthetic process | 0.0306867376359688 |
GO:0030800 | negative regulation of cyclic nucleotide metabolic process | 0.0306867376359688 |
GO:0008210 | estrogen metabolic process | 0.0375225372766592 |
GO:0045980 | negative regulation of nucleotide metabolic process | 0.0375225372766592 |
GO:0008517 | folic acid transporter activity | 0.0375225372766592 |
GO:0009058 | biosynthetic process | 0.0375225372766592 |
GO:0030817 | regulation of cAMP biosynthetic process | 0.0434324089209833 |
GO:0006704 | glucocorticoid biosynthetic process | 0.0434324089209833 |
GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 0.0445127194766519 |
GO:0030539 | male genitalia development | 0.047248571028189 |
GO:0005160 | transforming growth factor beta receptor binding | 0.047248571028189 |
GO:0030814 | regulation of cAMP metabolic process | 0.047248571028189 |
GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | 0.047248571028189 |
Relative expression of the co-expression cluster over median <br>Analyst:
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br>uberon_data<br><br>
Ontology term | p-value | n |
---|---|---|
gonad | 6.98e-58 | 18 |
gonad primordium | 6.98e-58 | 18 |
external genitalia | 3.36e-52 | 17 |
indifferent external genitalia | 3.36e-52 | 17 |
indifferent gonad | 3.36e-52 | 17 |
testis | 1.93e-44 | 14 |
reproductive organ | 3.79e-43 | 24 |
male reproductive organ | 2.02e-41 | 15 |
reproductive structure | 9.62e-40 | 26 |
reproductive system | 9.62e-40 | 26 |
male organism | 8.85e-39 | 16 |
male reproductive system | 8.85e-39 | 16 |
body cavity | 1.39e-27 | 37 |
body cavity or lining | 1.39e-27 | 37 |
body cavity precursor | 7.96e-27 | 38 |
anatomical cavity | 4.17e-26 | 39 |
anatomical space | 1.84e-17 | 57 |
immaterial anatomical entity | 3.23e-12 | 79 |
female gonad | 4.66e-09 | 3 |
mesoderm | 6.15e-09 | 120 |
mesoderm-derived structure | 6.15e-09 | 120 |
presumptive mesoderm | 6.15e-09 | 120 |
TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |